# OnCo record rejuv-paed-chronic-disease-burden (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/rejuv-paed-chronic-disease-burden/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "rejuv-paed-chronic-disease-burden" ;
  schema:name "How much illness childhood cancer survivors carry, and at what age"@en ;
  schema:description "The figures, with the cohort and the age attached, because they are misquoted more than any others. On self-report at a mean age of 26, 62.3 per cent of survivors had a chronic condition. On clinical testing, the cumulative prevalence of any chronic condition by age 45 was 95.5 per cent, and by age 50 a survivor had 17.1 conditions against 9.2 in matched controls."@en ;
  schema:url <https://onco.cc/technologies/rejuv-paed-chronic-disease-burden/> ;
  schema:dateModified "2026-10-02"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Chronic_condition> ;
  schema:citation <https://doi.org/10.1056/NEJMsa060185>, <https://doi.org/10.1001/jama.2013.6296>, <https://doi.org/10.1016/S0140-6736(17)31610-0>, <https://doi.org/10.1038/nrc3634> ;
  onco:status "established" ;
  onco:tag "rejuvenation", "survivorship", "paediatric", "late-effects", "evidence:strong" ;
  onco:related <https://onco.cc/trials/ccss/>, <https://onco.cc/collections/sjlife/>, <https://onco.cc/collections/bccss/>, <https://onco.cc/collections/pancaresurfup/>, <https://onco.cc/ideas/idea-acc-national-late-effects-registry/>, <https://onco.cc/ideas/idea-acc-survivor-biobank-late-effect-prediction/> ;
  onco:cancers <https://onco.cc/cancers/childhood-cancers/>, <https://onco.cc/cancers/all-leukemia/>, <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/neuroblastoma/>, <https://onco.cc/cancers/wilms-tumor/>, <https://onco.cc/cancers/medulloblastoma/>, <https://onco.cc/cancers/osteosarcoma/>, <https://onco.cc/cancers/ewing-sarcoma/> ;
  onco:sections <https://onco.cc/fronts/rejuvenation/>, <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/survivorship-care-plan/>, <https://onco.cc/technologies/rejuv-paed-late-mortality/>, <https://onco.cc/technologies/rejuv-paed-cog-ltfu-guidelines/>, <https://onco.cc/technologies/rejuv-age-frailty-and-late-effects/>, <https://onco.cc/technologies/rejuv-paed-growth-and-height/>, <https://onco.cc/technologies/rejuv-paed-pituitary-and-puberty/>, <https://onco.cc/technologies/rejuv-paed-neurocognitive/>, <https://onco.cc/technologies/rejuv-paed-hearing/>, <https://onco.cc/technologies/rejuv-paed-heart/>, <https://onco.cc/technologies/rejuv-paed-fertility-female/>, <https://onco.cc/technologies/rejuv-paed-fertility-male/>, <https://onco.cc/technologies/rejuv-paed-bone/>, <https://onco.cc/technologies/rejuv-paed-teeth-and-face/>, <https://onco.cc/technologies/rejuv-paed-kidneys/>, <https://onco.cc/technologies/rejuv-paed-second-cancers/>, <https://onco.cc/technologies/rejuv-paed-transition-to-adult-care/>, <https://onco.cc/technologies/rejuv-ayac-distinct-group/> ;
  onco:terms <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/quality-of-life/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-survivorship/> .